OBI Pharma, Inc. engages in the development and licensing of novel therapeutic agents for unmet medical needs against cancer. Its products include Adagloxad Simolenin, which is a late-stage novel active immune-oncology Globo Series-based therapeutic vaccine for the treatment of epithelial cancers, such as breast, ovarian, lung, prostate, colon, gastric, and pancreatic cancer. The company was founded by Michael N. Chang on April 29, 2002 and is headquartered in Taipei, Taiwan.
Fundamental metrics to determine fair value of the stock
Company’s recent performance and margins
Dividend yield, history and sustainability
Financial position and solvency of the company